

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	4
-------	---	----	---

**Complete if Known**

Application Number

Filing Date

**First Named Inventor**

David WALLACH

### Group Art Unit

1644

Examiner Name \_\_\_\_\_

Attorney Docket Number

WALLACH=12B

TO  
: [redacted]

09/800909



03/08/01

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner  
Signature

PHILIP GAMBIR 8/26/02

Date  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 4

**Complete if Known**

Application Number

09/800,909

Filing Date

First Named Inventor

David WALLACH

Group Art Unit

1644

Examiner Name

Attorney Docket Number

WALLACH=12B

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
AL		BALAVOINE et al, "Prostaglandin E <sub>2</sub> and Collagenase Production by Fibroblasts and Synovial Cells Is Regulated by Urine-Derived Human Interleukin 1 and Inhibitor(s)", <u>J Clin Invest</u> 78:1120-1124 (1986)	
AM		BEUTLER et al, "Passive Immunization against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin", <u>Science</u> 229:869-871 (1985)	
AN		BEUTLER et al, "Cachectin: More than a Tumor Necrosis Factor", <u>New Eng J Med</u> 316(7):379-385 (1987)	
AO		BEUTLER et al, <u>Tumor Necrosis Factors</u> ..., Raven Press, New York, pp. 145, 383 (1992)	
AP		BIGDA et al, "Dual Role of the p75 Tumor Necrosis Factor (TNF) Receptor in TNF Cytotoxicity", <u>J Exp Med</u> 180:445-460 (1994)	
AQ		BROCKHAUS et al, "Monoclonal Antibodies against the TNF-Receptor Inhibit ...", 2 <sup>nd</sup> Int'l Conf. Tumor Necrosis Factor and Related Cytokines, Jan 15-20, 1989, p. 140	
AR		BROCKHAUS et al, "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies", <u>Proc Natl Acad Sci U S A</u> 87(8):3127-3131 (1990)	
AS		CHEN et al, "Mapping the domain(s) critical for the binding of human tumor necrosis factor-alpha to its two receptors", <u>J Biol Chem</u> 270(6):2874-2878 (1995) (Abstract)	
AT		CORCORAN et al, "Characterization of ligand binding by the human p55 tumour-necrosis-factor receptor. Involvement of individual cysteine-rich repeats", <u>Eur J Biochem</u> 223(3):831-840 (1994)	
AU		CREASEY et al, "Biological Effects of Recombinant Human Tumor Necrosis Factor and Its Novel Muteins on Tumor and Normal Cell Lines", <u>Cancer Research</u> 47:145-149 (1987)	
AV		ENGELMANN et al, "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine", <u>J Biol Chem</u> 265(3):1531-1536 91990)	
AW		HARRIS et al, "Therapeutic antibodies - the coming of age", <u>TIBTECH</u> 11:42-44 (1993)	

Examiner  
Signature

Philip Gamba 8/26/02

Date  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3

of

4

**Complete if Known**

Application Number

09/800/909

Filing Date

First Named Inventor

David WALLACH

Group Art Unit

1644

Examiner Name

Attorney Docket Number

WALLACH=12B

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
RG	AX	HOHMANN et al, "Two Different Cell Types Have Different Major Receptors for Human Tumor Necrosis Factor (TNFalpha)", <u>J Biol Chem</u> 264(25):14927-14934 (1989)	
	AY	HOHMANN et al, "Two Different Cell Types Have Different Major Receptors for Human Tumor Necrosis Factor (TNFalpha)", 2 <sup>nd</sup> Int'l Conf. Tumor Necrosis Factor and Related Cytokines, Jan 15-20, 1989, p. 143	
	AZ	LOETSCHER et al, "Purification and partial amino acid sequence analysis of two distinct tumor necrosis factor receptors from HL60 cells", <u>J Biol Chem</u> 265(33):20131-20138 (1990)	
	BA	NATANSON et al, "Selected Treatment Strategies for Septic Shock Based on Proposed Mechanisms of Pathogenesis", <u>Annals of Int Med</u> 120(9):771-783 (1994)	
	BB	PARRILLO JE, "Pathogenetic Mechanisms of Septic Shock", <u>New Eng J Med</u> 328(20):1471-1477 (1993)	
	BC	PEETRE et al, "A tumor necrosis factor binding protein is present in human biological fluids", <u>Eur J Haematol</u> 41:414-419 (1988)	
	BD	SCHALL et al, "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor", <u>Cell</u> 61:361-370 (1990)	
	BE	SECKINGER et al, "A Human Inhibitor of Tumor Necrosis Factor alpha", <u>J Exp Med</u> 167:1511-1516 (1988)	
	BF	SMITH et al, "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins", <u>Science</u> 248:1019-1023 (1990)	
	BG	STAUBER et al, "Human Tumor Necrosis Factor-alpha Receptor", <u>J Biol Chem</u> 263(35):19098-19104 (1986)	
	BH	TRACEY et al, "Shock and Tissue Injury Induced by Recombinant Human Cachectin", <u>Science</u> 234:470-474 (1986)	
	BI	TRACEY et al, "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia" <u>Nature</u> 330:662-664 (1987)	

Examiner  
Signature

Philip Ganga Stefan

Date  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	4
-------	---

4

o

4

**Complete if Known**

Application Number

09/800,909

Filing Date

**First Named Inventor**

**David WALLACH**

### Group Art Unit

1644

Examiner Name

Attorney Docket Number

WALLACH=12B

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner  
Signature

PAUL GARDNER Skelton

Date  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.